Fat-Processing Gene Variants Tied to Lymphoma Risk and Survival

A team of hematologists in China has uncovered evidence that tiny inherited spelling differences in genes governing how the body handles fats may help determine who develops one of the most common and unpredictable blood cancers, and how those patients fare once treatment begins. The study, published in Annals of Hematology, examined diffuse large B-cell lymphoma, an aggressive malignancy of antibody-producing B cells that has long frustrated clinicians with its biological heterogeneity: two patients with seemingly identical diagnoses can respond in strikingly different ways to the same therapy.

The researchers, led by Xuan Liu, Xiao Han, Chenchen Ning, Boya Li, Yihua Pang, Jingjing Ye, Dongmei Wang, Fei Lu and Chunyan Ji of Qilu Hospital of Shandong University in Jinan, focused on single-nucleotide polymorphisms, or SNPs, the single-letter variations in DNA that dot the human genome by the millions. Most SNPs are harmless, but some alter the activity or structure of the proteins a gene encodes, subtly shifting cellular machinery. Because cancer cells are notorious for rewiring their metabolism, and lipid metabolism in particular has emerged as a fuel source and signaling hub for tumor growth, the team asked whether variants in fat-processing genes might influence lymphoma susceptibility and outcomes.

To find out, the investigators genotyped ten SNPs drawn from eight lipid metabolism-related genes in 148 patients with diffuse large B-cell lymphoma and 230 healthy controls. They then cross-referenced the genetic data against clinical records, including disease stage, risk stratification, response to chemotherapy, and survival. The design is a classic genetic association study: rather than manipulating genes in the laboratory, it looks for statistical correlations between inherited variants and disease traits in real populations, a strategy that can flag genes worth probing in functional experiments.

The results were striking in their breadth. One variant, PRKAG2 rs2727572, was associated with susceptibility to the disease itself, suggesting that this gene, which encodes a regulatory subunit of the AMP-activated protein kinase complex, a central energy sensor in cells, may play a role in whether lymphoma takes hold in the first place. AMPK acts as a metabolic master switch, and disruptions to its regulation have been implicated in several cancers, making the association biologically plausible rather than a mere statistical curiosity.

Two other variants tracked with disease severity. CPT2 rs1799822 was related to the Ann Arbor stage, the standard staging system that describes how far lymphoma has spread through the lymphatic system and beyond. CPT2 encodes carnitine palmitoyltransferase 2, an enzyme essential for shuttling fatty acids into mitochondria, where they are burned for energy, so a variant that alters its function could influence how tumor cells fuel their expansion. Meanwhile, CYP19A1 rs10046 was associated with risk stratification, a classification that guides how aggressively patients are treated. CYP19A1 encodes aromatase, an enzyme that converts androgens into estrogens, linking fat biology to hormone signaling in ways that may matter for lymphoma biology.

Perhaps most clinically provocative was the finding involving FABP1 rs2197076, which was correlated with treatment response, particularly the rate of complete remission following chemotherapy. FABP1 encodes a fatty acid-binding protein that shuttles lipids within cells, and if inherited differences in this gene influence how patients respond to standard chemotherapy regimens, the variant could eventually help oncologists anticipate which patients are likely to achieve a full remission and which may need alternative or intensified approaches from the outset.

Survival, too, appeared to be shaped by lipid genetics. Different genotype frequencies of CES1 rs8192950 were associated with survival, indicating potential value for prognostic stratification. CES1 encodes carboxylesterase 1, an enzyme involved in lipid processing and in the metabolism of many drugs, raising the possibility that this variant influences both tumor behavior and the pharmacology of treatment. If validated, such a marker could join the growing arsenal of prognostic tools that help clinicians sort patients into risk groups and tailor follow-up intensity accordingly.

Taken together, the findings suggest that lipid metabolism-related SNPs may influence the pathogenesis and progression of diffuse large B-cell lymphoma at multiple points along the disease course, from initial susceptibility through staging, treatment response, and ultimately survival. That a single panel of ten variants from eight genes could touch so many clinical dimensions underscores how deeply metabolism is woven into cancer biology, and how inherited variation outside the tumor itself can shape the trajectory of a malignancy.

The authors are careful to note the limits of their work. The study is constrained by its sample size of 148 patients and 230 controls, and it lacks an independent validation cohort, the gold standard for confirming that genetic associations hold up in a separate population. Genetic association studies are also prone to false positives when many variants are tested, so each finding must be treated as a hypothesis generator rather than a settled conclusion. Still, the team argues that the results provide novel insights that may inform future functional studies and therapeutic exploration, potentially pointing toward metabolic pathways that could be targeted with drugs or used to refine risk prediction in this heterogeneous and challenging disease.

Subject of Research: Association of lipid metabolism gene polymorphisms with susceptibility and prognosis in diffuse large B-cell lymphoma

Article Title: Lipid metabolism-related gene polymorphisms are associated with susceptibility and clinical outcomes in diffuse large B-cell lymphoma

Article References: Liu, X., Han, X., Ning, C., Li, B., Pang, Y., Ye, J., Wang, D., Lu, F., & Ji, C. (2026). Lipid metabolism-related gene polymorphisms are associated with susceptibility and clinical outcomes in diffuse large B-cell lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-026-07316-2

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07316-2

Keywords: diffuse large B-cell lymphoma, lipid metabolism, single-nucleotide polymorphisms, genetic association study, cancer metabolism, PRKAG2, CPT2, CYP19A1, FABP1, CES1, prognosis, hematology